Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly qualified and experienced EU-dQPPV to join our dynamic team and will report to the QPPV. The Deputy EU Qualified Person for Pharmacovigilance (Deputy EU QPPV) serves as the designated deputy to the EU QPPV and supports the oversight, maintenance, and continuous improvement of the company's European pharmacovigilance (PV) system. The role ensures compliance with European Union pharmacovigilance legislation, Good Pharmacovigilance Practices (GVP), and applicable local requirements. The Associate Director, Deputy QPPV supports the QPPV in maintaining, executing, and continuously improving a fully compliant global Pharmacovigilance system. In the absence of the QPPV, this individual assumes full legal and functional responsibility for the safety of all marketed products and products under clinical development.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior